Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Equity Ratio (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Equity Ratio for 15 consecutive years, with 0.75 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 1.91% year-over-year to 0.75, compared with a TTM value of 0.75 through Sep 2025, down 1.91%, and an annual FY2024 reading of 0.75, down 1.89% over the prior year.
  • Equity Ratio was 0.75 for Q3 2025 at Alaunos Therapeutics, down from 0.77 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.83 in Q2 2021 and bottomed at 0.48 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.69, with a median of 0.75 recorded in 2024.
  • The sharpest move saw Equity Ratio skyrocketed 49.95% in 2023, then tumbled 37.21% in 2025.
  • Year by year, Equity Ratio stood at 0.61 in 2021, then dropped by 2.98% to 0.59 in 2022, then increased by 28.56% to 0.76 in 2023, then decreased by 1.89% to 0.75 in 2024, then grew by 0.52% to 0.75 in 2025.
  • Business Quant data shows Equity Ratio for TCRT at 0.75 in Q3 2025, 0.77 in Q2 2025, and 0.5 in Q1 2025.